Drug Trial Radar · NCT05604170
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
117
Actual
Start
May 16, 2022
Primary completion
Apr 2, 2025
Study completion Apr 2, 2025
Sponsor
- Lead sponsor
- Marinus PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001
Conditions
- Tuberous Sclerosis Complex
Interventions
GanaxoloneDrug
GNX will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Withdrawals and Dose-Reductions Due to AEsTime frame: Up to 150 Weeks
- Number of Participants With Clinically Significant Changes in Vital ParametersTime frame: Up to 150 Weeks
- Number of Participants With Clinically Significant Changes in Physical ExaminationsTime frame: Up to 150 Weeks
- Number of Participants With Clinically Significant Changes in Neurological ExaminationsTime frame: Up to 150 Weeks
- Number of Participants With Clinically Significant Changes in Developmental ExaminationsTime frame: Up to 150 Weeks
- Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) FindingsTime frame: Up to 150 Weeks
- Number of Participants With Clinically Significant Changes in Hematology ParametersTime frame: Week 1 through Week 150
- Number of Participants With Clinically Significant Changes in Chemistry ParametersTime frame: Up to 150 Weeks
- Number of Participants With Clinically Significant Changes in UrinalysisTime frame: Up to 150 Weeks
- Number of Participants (Age Greater Than 17 Years) With Abnormal Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Week 52
Locations
54 sites in 10 countries. Site status is shown where the registry gives one.
Arkansas Children's Research Institute
Little Rock, Arkansas
UCLA Mattel Children's Hospital, TSC Center
Los Angeles, California
Children's Hospital of Orange County
Orange, California
Rady Children's Hospital - San Diego
San Diego, California
Children's Hospital Colorado
Aurora, Colorado
Nemours Children's Hospital - Delaware Valley
Wilmington, Delaware
Boston Children's Hospital, Harvard Medical School
Boston, Massachusetts
Mayo Clinic - Rochester
Rochester, Minnesota
Children's Mercy Hospital
Kansas City, Missouri
University of Rochester Medical Center
Rochester, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Atrium Health/Levine Children's Hospital
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Le Bonheur Children's Hospital
Memphis, Tennessee
Child Neurology Consultants of Austin (CNCA)
Austin, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
McGovern Medical School at the University of Texas Health Science Center
Houston, Texas
University of Utah Health Care-Pediatric Neurology
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
Austin Health
Heidelberg, Australia
Royal Brisbane and Women's Hospital
Herston, Australia
Alfred Health
Melbourne, Australia
Royal Melbourne Hospital
Parkville, Australia
Hôtel Dieu de Montréal - CHUM
Montreal, Canada
CHU Sainte-Justine
Montreal, Canada
The Hospital for Sick Children
Toronto, Canada
Toronto Western Hospital
Toronto, Canada
BC Children's Hospital
Vancouver, Canada
Peking University First Hospital
Beijing, China
Beijing Children Hospital, Capital Medical University
Beijing, China
Chinese PLA General Hospital
Beijing, China
The Affiliated Hospital of Guizhou Medical University
Beijing, China
First Hospital of Jilin University
Jilin City, China
University Hospital of Lyon
Bron, France
Hôpital Sud
Rennes, France
University of Strasbourg
Strasbourg, France
Epilepsie-Zentrum Bethel - Krankenhaus Mara
Bielefeld, Germany
University Hospital Bonn
Bonn, Germany
ZNN - Epilepsiezentrum Frankfurt am Main
Frankfurt, Germany
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.